BRCA1 and breast carcinoma: Furthermore, the combined therapy of double immune checkpoint inhibitors (ICIs), such as anti-PD1 and anti-CTLA4, with chemotherapy provoked strong systemic and intratumoral immune responses in BRCA1-mutated breast cancer [46].